Related Experiment Videos

Strategies to reduce the GI risks of antiplatelet therapy

James M Scheiman1

  • 1Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA.

Reviews in Cardiovascular Medicine
|December 6, 2007
PubMed

Insights

Low-dose aspirin, while crucial for cardiovascular health, can cause upper gastrointestinal issues. Strategies like gastroprotective agents and Helicobacter pylori eradication help mitigate these risks.

Area of Science:

  • Gastroenterology
  • Cardiology
  • Pharmacology

Background:

  • Low-dose aspirin and other antiplatelet agents are standard for cardiovascular disease management.
  • Aspirin and NSAIDs inhibit cyclooxygenase, leading to upper gastrointestinal (GI) side effects like ulcers and bleeding.
  • Aspirin-related toxicity is a significant healthcare concern due to widespread use, despite lower risk than NSAIDs alone.

Purpose of the Study:

  • To review risk factors for aspirin-induced upper GI complications.
  • To discuss strategies for minimizing GI side effects in patients taking aspirin.
  • To evaluate alternative antiplatelet agents for high-risk patients.

Main Methods:

  • Literature review of studies on aspirin, NSAIDs, and GI complications.
  • Analysis of risk factors including prior ulcer history, aspirin dose, and concomitant medications.
  • Evaluation of gastroprotective strategies and alternative antiplatelet therapies.

Main Results:

  • Prior ulcer history, higher aspirin dose, and concurrent use of NSAIDs, anticoagulants, or antiplatelets increase GI risk.
  • Proton pump inhibitors and prostaglandin analogues show effectiveness in gastroprotection.
  • Eradication of Helicobacter pylori may reduce ulcer risk.
  • Clopidogrel monotherapy is not a safer alternative for high-risk patients.

Conclusions:

  • Managing cardiovascular disease with aspirin requires balancing benefits against GI risks.
  • Proactive gastroprotection and risk factor modification are essential for patients on aspirin.
  • Alternative antiplatelet strategies need careful consideration for high-risk individuals.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...